Vnitr Lek 2018, 64(5):526-529 | DOI: 10.36290/vnl.2018.074

Diagnosis and treatment of immune thrombocytopenia

Libor Červinek
Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice

The diagnosis of immune thrombocytopenia consists in the combination of laboratory and clinical pictures of thrombocytopenia while eliminating other disorders characterized by low levels of thrombocytes. The treatment initiation in patients with ITP is recommended when the thrombocyte count has dropped below 20-30 × 109/l, when hemorrhagic manifestations occur and depending on the patient's risk profile. Corticoids and IVIG are used as first-line treatment. Second-line treatment includes splenectomy, immunosuppressive therapy and administration of thrombopoietin receptor agonists. A new drug in the treatment of ITP is fostamatinib.

Keywords: corticoids; eltrombopag; fostamatinib; immune thrombocytopenia; IVIG; rituximab; romiplostim; sustainable remission; splenectomy

Received: November 28, 2017; Accepted: March 17, 2018; Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Červinek L. Diagnosis and treatment of immune thrombocytopenia. Vnitr Lek. 2018;64(5):526-529. doi: 10.36290/vnl.2018.074.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rodeghiero F, Stasi R. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113(11): 2386-2393. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2008-07-162503>. Go to original source... Go to PubMed...
    2. Provan D, Stasi R, Newland A et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115(2): 168-186. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2009-06-225565>. Go to original source... Go to PubMed...
    3. Neunert C, Lim W, Crowther M et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117(16): 4190-4207. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2010-08-302984>. Go to original source... Go to PubMed...
    4. Portielje J, Westendorp R, Klui-Nelemans H et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97(9): 2549-2554. Go to original source... Go to PubMed...
    5. Godeau B, Lesage S, Divine M et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993; 82(5): 1415-1421. Go to original source...
    6. Zoghlami-Rintelen C, Weltrmann A, Bittermann C et al. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia. Ann Hematol 2003; 82(5): 290-294. Dostupné z DOI: <http://dx.doi.org/10.1007/s00277-002-0550-8>. Go to original source... Go to PubMed...
    7. Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357(22): 2237-2247. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa073275>. Go to original source... Go to PubMed...
    8. Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371(9610): 395-403. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(08)60203-2>. Go to original source... Go to PubMed...
    9. Bussel JB, Kuter DJ, Pullarkat V et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113(10): 2161-2171. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2008-04-150078>. Erratum in Blood 2009; 113(19): 4822. Go to original source... Go to PubMed...
    10. Červinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol 2015; 102(1): 7-11. Dostupné z DOI: <http://dx.doi.org/10.1007/s12185-015-1793-1>. Go to original source... Go to PubMed...
    11. González-López TJ, Pascual C, Álvarez-Román MT et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015; 90(3): E40-E43. Dostupné z DOI: <http://dx.doi.org/10.1002/ajh.23900>. Go to original source... Go to PubMed...
    12. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001; 114(1): 121-125. Go to original source... Go to PubMed...
    13. Reiner A, Gernsheimer T, Schlichter SJ. Pulse cyclofosfamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85(2): 351-358. Go to original source...
    14. Maloisel F, Andres E, Zimmer J et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura. Am J Med 2004; 116(9): 590-594. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2003.12.024>. Go to original source... Go to PubMed...
    15. Howard J, Hoffbrand AV, Prentice HG et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anemia and autoimmune thrombocytopenic purpura. Br J Haematol 2002; 117(3): 712-715. Go to original source... Go to PubMed...
    16. Ghanima W, Khelif A, Waage A et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 385(9978): 1653-1661. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(14)61495-1>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.